NITE - Nightstar Therapeutics plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Nightstar Therapeutics plc

215 Euston Road
London NW1 2BE
United Kingdom
44 20 7611 2077

Full Time Employees27

Key Executives

NameTitlePayExercisedYear Born
Mr. David FellowsCEO & DirectorN/AN/A1957
Mr. Senthil SundaramCFO & Principal Accounting OfficerN/AN/A1978
Dr. Gregory Robinson Ph.D.Chief Scientific OfficerN/AN/A1959
Mr. Aniz GirachChief Medical OfficerN/AN/AN/A
Dr. Tuyen Ong M.D., MRCOphth, MBAExec. VP & Chief Devel. OfficerN/AN/A1975
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate includes NSR-REP1, a candidate that has completed Phase 1/2 clinical trial for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trial for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. The company was founded in 2013 and is headquartered in London, the United Kingdom.

Corporate Governance

Nightstar Therapeutics plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.